Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of quadrivalent influenza vaccine versus Fluarix in children aged 6 to 35 months
2013-003155-38Phase 3
- Sponsor
- GSK
- Start
- May 2015
- Modality
- Vaccines & Immunotherapeutics, Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of influenza virus quadrivalent inactivated vaccine and Fluarix in influenza (2 arms), sponsored by GSK. Primary endpoints: Humoral immune response to each strain of FLU Q-QIV and Immunogenic superiority of B/Victoria strain.
02
Drugs
influenza virus quadrivalent inactivated vaccineFluarix
03
Conditions
influenza
Beyond the preview
Go deeper on 2013-003155-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003155-38.